Adial Pharmaceuticals Inc ADIL:NASDAQ

Last Price$1.20NASDAQ Previous Close - Last Trade as of 4:00PM ET 7/01/22

Today's Change-0.14(10.45%)
Bid (Size)$1.21 (5)
Ask (Size)$1.29 (1)
Day Low / High$1.19 - 1.34
Volume274.8 K

View Pharmaceuticals: Major IndustryPeer Comparison as of 07/01/2022


Adial Pharmaceuticals Inc ( NASDAQ )

Price: $1.20
Change: -0.14 (10.45%)
Volume: 274.8 K
4:00PM ET 7/01/2022

Abeona Therapeutics Inc ( NASDAQ )

Price: $0.19
Change: -0.02 (7.88%)
Volume: 2.8 M
4:00PM ET 7/01/2022

Amexdrug Corp ( OTC )

Price: $0.17
Change: 0.00 (0.00%)
Volume: 17.00
10:10AM ET 5/12/2022

GlycoMimetics Inc ( NASDAQ )

Price: $0.56
Change: -0.03 (5.77%)
Volume: 116.8 K
4:00PM ET 7/01/2022

Onconova Therapeutics Inc ( NASDAQ )

Price: $1.30
Change: -0.03 (1.89%)
Volume: 31.2 K
4:00PM ET 7/01/2022

Read more news Recent News

Adial Pharmaceuticals Locks Database for Late-Stage Alcohol Use Disorder Trial, Sees Topline Results in July
11:19AM ET 6/27/2022 MT Newswires

Adial Pharmaceuticals (ADIL) said Monday it has locked database for its phase 3 study of AD04 in patients with alcohol use disorder and selected...

Adial Pharmaceuticals Secures New US Patent For Alcohol, Drug Dependence Treatment
11:18AM ET 6/14/2022 MT Newswires

Adial Pharmaceuticals (ADIL) said Tuesday that it secured a new patent in the US covering the combined use of its genetic diagnostic panel with its lead...

Adial Pharmaceuticals Working With Medical College of Wisconsin to Evaluate Adenosine Analogs
11:11AM ET 5/19/2022 MT Newswires

Adial Pharmaceuticals (ADIL) said Thursday its Purnovate unit has entered into a research partnership with the Medical College of Wisconsin. The...

Adial Pharmaceuticals Teams Up With UC San Diego to Test Adenosine Compounds as Treatment for Inflammatory Diseases
12:33PM ET 5/04/2022 MT Newswires

Adial Pharmaceuticals (ADIL) said Wednesday its Purnovate unit has entered into a research collaboration agreement with the University of California San...

View all Commentary and Analysis

No news stories available at this time.

Company Profile

Business DescriptionAdial Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the treatment of alcohol use disorder. Its lead product is AD04, a selective serotonin-3 antagonist. The company was founded by Bankole A. Johnson in November 2010 and is headquartered in Charlottesville, VA. View company web site for more details
Address1180 Seminole Trail
Charlottesville, Virginia 22901
Number of EmployeesN/A
Recent SEC Filing06/29/2022EFFECT
President, Chief Executive Officer & DirectorWilliam B. Stilley
Chief Operating Officer & DirectorCary J. Claiborne
Chief Financial Officer, Secretary & TreasurerJoseph Truluck
Chief Medical OfficerBankole A. Johnson

Company Highlights

Price Open$1.34
Previous Close$1.34
52 Week Range$1.04 - 5.08
Market Capitalization$28.5 M
Shares Outstanding23.8 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement08/11/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.82
Beta vs. S&P 500N/A
Net Profit MarginN/A
Return on Equity-266.69%

Analyst Ratings as of 06/27/2022

Consensus RecommendationConsensus Icon
Powered by Factset